Diversity of intratumoral regulatory T cells in B-cell non-Hodgkin lymphoma.


Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
12 Dec 2023
Historique:
accepted: 28 08 2023
received: 08 03 2023
medline: 1 12 2023
pubmed: 11 9 2023
entrez: 11 9 2023
Statut: ppublish

Résumé

Tumor-infiltrating regulatory T cells (Tregs) contribute to an immunosuppressive tumor microenvironment. Despite extensive studies, the prognostic impact of tumor-infiltrating Tregs in B-cell non-Hodgkin lymphomas (B-NHLs) remains unclear. Emerging studies suggest substantial heterogeneity in the phenotypes and suppressive capacities of Tregs, emphasizing the importance of understanding Treg diversity and the need for additional markers to identify highly suppressive Tregs. Here, we applied single-cell RNA sequencing and T-cell receptor sequencing combined with high-dimensional cytometry to decipher the heterogeneity of intratumoral Tregs in diffuse large B-cell lymphoma and follicular lymphoma (FL), compared with that in nonmalignant tonsillar tissue. We identified 3 distinct transcriptional states of Tregs: resting, activated, and unconventional LAG3+FOXP3- Tregs. Activated Tregs were enriched in B-NHL tumors, coexpressed several checkpoint receptors, and had stronger immunosuppressive activity compared with resting Tregs. In FL, activated Tregs were found in closer proximity to CD4+ and CD8+ T cells than other cell types. Furthermore, we used a computational approach to develop unique gene signature matrices, which were used to enumerate each Treg subset in cohorts with bulk gene expression data. In 2 independent FL cohorts, activated Tregs was the major subset, and high abundance was associated with adverse outcome. This study demonstrates that Tregs infiltrating B-NHL tumors are transcriptionally and functionally diverse. Highly immunosuppressive activated Tregs were enriched in tumor tissue but absent in the peripheral blood. Our data suggest that a deeper understanding of Treg heterogeneity in B-NHL could open new paths for rational drug design, facilitating selective targeting to improve antitumor immunity.

Identifiants

pubmed: 37695745
pii: 497828
doi: 10.1182/bloodadvances.2023010158
pmc: PMC10698546
doi:

Substances chimiques

Immunosuppressive Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

7216-7230

Informations de copyright

© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

Références

Front Immunol. 2022 Jul 19;13:909008
pubmed: 35928819
Science. 2014 Dec 19;346(6216):1536-40
pubmed: 25525252
Cancers (Basel). 2020 Dec 26;13(1):
pubmed: 33375291
Nat Rev Clin Oncol. 2019 Jun;16(6):356-371
pubmed: 30705439
Bioinformatics. 2021 Oct 11;37(19):3374-3376
pubmed: 33774659
Nat Med. 2013 Jun;19(6):739-46
pubmed: 23624599
Nat Med. 2011 Jul 24;17(8):975-82
pubmed: 21785433
Nat Rev Immunol. 2008 Jul;8(7):523-32
pubmed: 18566595
Nat Biotechnol. 2019 Jul;37(7):773-782
pubmed: 31061481
Cancer Immunol Res. 2016 Sep 2;4(9):721-5
pubmed: 27590281
Front Immunol. 2021 Feb 26;12:625783
pubmed: 33717139
Lancet Oncol. 2015 Sep;16(9):1111-1122
pubmed: 26256760
Nat Med. 2022 Sep;28(9):1860-1871
pubmed: 36097223
J Clin Oncol. 2009 Mar 20;27(9):1470-6
pubmed: 19224853
Nat Med. 2022 Sep;28(9):1872-1882
pubmed: 36038629
Cancer Discov. 2020 Mar;10(3):406-421
pubmed: 31857391
Cell Rep. 2022 Apr 19;39(3):110713
pubmed: 35443163
J Exp Med. 2014 Jan 13;211(1):121-36
pubmed: 24378538
Cancer Immunol Res. 2013 Jul;1(1):32-42
pubmed: 24777248
J Immunol. 2019 Mar 1;202(5):1397-1405
pubmed: 30692213
iScience. 2021 Jan 09;24(2):102053
pubmed: 33537658
Cell. 2017 Sep 7;170(6):1096-1108.e13
pubmed: 28886380
Br J Cancer. 2013 Nov 12;109(10):2629-35
pubmed: 24169351
Blood. 2021 May 27;137(21):2869-2880
pubmed: 33728464
Bioinformatics. 2011 Jun 15;27(12):1739-40
pubmed: 21546393
Nat Med. 2011 Jul 24;17(8):983-8
pubmed: 21785430
Nat Commun. 2017 Apr 21;8:15067
pubmed: 28429709
Ther Adv Hematol. 2021 Oct 30;12:20406207211053120
pubmed: 34733463
Nat Cell Biol. 2020 Jul;22(7):896-906
pubmed: 32541878
Haematologica. 2008 Feb;93(2):193-200
pubmed: 18223287
Int J Mol Sci. 2019 Jun 02;20(11):
pubmed: 31159473
Nat Immunol. 2003 Apr;4(4):330-6
pubmed: 12612578
J Clin Oncol. 2006 Dec 1;24(34):5350-7
pubmed: 17135637
Blood. 2010 Jan 14;115(2):289-95
pubmed: 19901260
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
Trends Immunol. 2006 Apr;27(4):183-7
pubmed: 16527542
J Clin Oncol. 2007 Feb 1;25(4):390-8
pubmed: 17200149
Immunity. 2016 Nov 15;45(5):1122-1134
pubmed: 27851913
J Immunol. 2000 Jan 1;164(1):183-90
pubmed: 10605010
Sci Transl Med. 2018 Jan 31;10(426):
pubmed: 29386357
Immunol Cell Biol. 2014 Jul;92(6):475-80
pubmed: 24732076
Am J Clin Pathol. 2015 Dec;144(6):935-44
pubmed: 26573001
Immunity. 2019 Feb 19;50(2):493-504.e7
pubmed: 30737144
Science. 2021 Jul 16;373(6552):
pubmed: 34437125
Cell Syst. 2015 Dec 23;1(6):417-425
pubmed: 26771021
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Immunity. 2016 Nov 15;45(5):1135-1147
pubmed: 27851914
Nat Med. 2018 Jul;24(7):978-985
pubmed: 29942094
Blood. 2006 Nov 1;108(9):2957-64
pubmed: 16825494
Blood Cancer Discov. 2022 Sep 6;3(5):428-443
pubmed: 35687817
Nature. 2019 Jun;570(7759):112-116
pubmed: 31092922
Nat Immunol. 2021 Aug;22(8):1052-1063
pubmed: 34168370
Sci Rep. 2015 Oct 14;5:15179
pubmed: 26462617
Clin Cancer Res. 2019 Feb 15;25(4):1233-1238
pubmed: 30054281
J Exp Med. 2013 Aug 26;210(9):1695-710
pubmed: 23897981
J Immunol. 2018 May 15;200(10):3647-3661
pubmed: 29661826
Sci Immunol. 2021 Feb 12;6(56):
pubmed: 33579751
Methods Mol Biol. 2020;2117:135-157
pubmed: 31960376
J Transl Med. 2009 Oct 22;7:89
pubmed: 19849846
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008
pubmed: 31028147
Cancer Cell. 2021 Oct 11;39(10):1422-1437.e10
pubmed: 34597589
Nat Immunol. 2016 Nov;17(11):1322-1333
pubmed: 27595233
Cell. 2017 Jun 15;169(7):1342-1356.e16
pubmed: 28622514
Blood. 2023 Feb 2;141(5):467-480
pubmed: 36322929
Leukemia. 2012 May;26(5):1053-63
pubmed: 22015774
Immunity. 2019 Feb 19;50(2):302-316
pubmed: 30784578
Leukemia. 2017 Oct;31(10):2181-2190
pubmed: 28119525
Haematologica. 2019 Oct;104(10):e460-e464
pubmed: 30846496
Cancer Immunol Immunother. 2021 Sep;70(9):2417-2427
pubmed: 33576875
J Immunol. 2018 Apr 1;200(7):2362-2371
pubmed: 29459403
Immunity. 2009 Jun 19;30(6):899-911
pubmed: 19464196

Auteurs

Ivana Spasevska (I)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Ankush Sharma (A)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Chloé B Steen (CB)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Division of Oncology, Stanford University School of Medicine, Stanford, CA.

Sarah E Josefsson (SE)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.

Yngvild N Blaker (YN)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.

Arne Kolstad (A)

KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.
Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway.

Even H Rustad (EH)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Saskia Meyer (S)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Kathrine Isaksen (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Stalin Chellappa (S)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Kushi Kushekhar (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.

Klaus Beiske (K)

KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway.

Mette S Førsund (MS)

Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway.

Signe Spetalen (S)

Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway.

Harald Holte (H)

KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway.

Bjørn Østenstad (B)

KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway.

Marianne Brodtkorb (M)

KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway.

Eva Kimby (E)

Department of Hematology, Karolinska Institute, Stockholm, Sweden.

Johanna Olweus (J)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Institute of Clinical Medicine, University of Oslo, Norway.

Kjetil Taskén (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.

Aaron M Newman (AM)

Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA.

Susanne Lorenz (S)

Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.

Erlend B Smeland (EB)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Ash A Alizadeh (AA)

Division of Oncology, Stanford University School of Medicine, Stanford, CA.
Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA.

Kanutte Huse (K)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

June H Myklebust (JH)

Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.
Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH